Cost-effectiveness league tables: valuable guidance for decision makers?

Pharmacoeconomics. 2003;21(14):991-1000. doi: 10.2165/00019053-200321140-00001.

Abstract

This paper asks the question 'are cost-effectiveness league tables a good way to provide information to decision makers about the value of new healthcare interventions?' League tables that rank alternative healthcare interventions based on their incremental cost-effectiveness ratios (ICERs) are seen by economists as a valuable tool to inform decision makers about the allocation of scarce healthcare resources. However, league tables frequently compare ICERs from studies that have computed these ratios using different methods and assumptions including choice of comparator, choice of discount rate, time horizon, and population subgroup. The methodological differences among studies may influence the ranking of the studies and therefore decisions made using the league table. In addition, league tables generally do not include measures of the uncertainty of the cost-effectiveness estimates. In this paper, a reference case approach is proposed for the computation of the incremental cost-effectiveness ratio and an expanded set of measures is proposed for inclusion in the league table. In addition, a central repository for reference case expanded league tables is suggested so that decision makers can use them more effectively and more consistently.

MeSH terms

  • Cost-Benefit Analysis / methods
  • Decision Making*
  • Delivery of Health Care / economics*
  • Drug Therapy / economics*
  • Health Care Costs
  • Humans
  • Quality-Adjusted Life Years